EYE103 for Diabetic Eye Conditions
(AMARONE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new treatment called EYE103 for patients with specific eye conditions. It aims to reduce swelling and abnormal blood vessel growth in the eye. The study will check if EYE103 is safe and effective.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you are a DME patient, you must not have received any prior treatment for your condition.
Are You a Good Fit for This Trial?
This trial is for adults with diabetic macular edema (DME) who are at least 18 years old and have not been treated before, or those with neovascular age-related macular degeneration (NVAMD) who are 50 or older. Participants must understand the study, agree to its procedures, and have vision loss in the affected eye.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Multiple Ascending Dose (MAD) Safety Study
The safety of EYE103 is assessed at escalating doses in approximately 12 participants
Dose-finding Comparative Safety and Efficacy Study
Two doses of EYE103 are selected and their effectiveness is compared in approximately 80 participants
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- EYE103
Find a Clinic Near You
Who Is Running the Clinical Trial?
EyeBiotech Ltd.
Lead Sponsor